Literature DB >> 6608378

On the mechanism for the red-cell accumulation of mefloquine, an antimalarial drug.

R C San George, R L Nagel, M E Fabry.   

Abstract

The accumulation of the antimalarial drug mefloquine by human red blood cells has been studied by 19F-NMR spectroscopy. The uptake process was nonlinearly dependent on the external drug concentration. Concentrations inside cells as high as 60-times greater than those in the extracellular phosphate-buffered-saline were observed. Red-cell ghosts were also found to accumulate mefloquine with high-affinity binding sites for the drug. Hemoglobin was found to bind mefloquine with low affinity, but due to the high concentration of this protein it is a significant drug compartment in the red cell. Analysis of the 19F-NMR chemical shifts and linewidths of mefloquine in the presence of red cells, red-cells ghosts and hemoglobin indicates restricted mobility of the drug in the membrane-bound state and slow exchange with the extracellular medium. This is a significant characteristic of the reaction in connection with the prophylactic activity of the drug. Exchange of the drug between hemoglobin and the red-cell membrane, however, is fast and may play an important role in the bioavailability of the drug to the parasite.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608378     DOI: 10.1016/0167-4889(84)90007-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

1.  The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase.

Authors:  L Lu; F Leonessa; M T Baynham; R Clarke; F Gimenez; Y T Pham; F Roux; I W Wainer
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Mefloquine pharmacokinetics in healthy subjects and in peptic ulcer patients after cimetidine administration.

Authors:  J A Kolawole; A Mustapha; I Abudu-Aguye; N Ochekpe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

3.  Carrier-mediated partitioning of artemisinin into Plasmodium falciparum-infected erythrocytes.

Authors:  Nehal Vyas; Bonnie A Avery; Mitchell A Avery; Christy M Wyandt
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Divided-dose kinetics of mefloquine in man.

Authors:  G Franssen; B Rouveix; J Lebras; J Bauchet; F Verdier; C Michon; F Bricaire
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

5.  Investigation of the in vitro gender-specific partitioning of mefloquine in malarial infected red blood cells and plasma.

Authors:  Nongluk Seethorn; Walther H Wernsdorfer; Harald Noedl; Juntra Karbwang; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2013-09-03       Impact factor: 2.345

Review 6.  Clinical pharmacokinetics of mefloquine.

Authors:  J Karbwang; N J White
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

7.  First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity.

Authors:  Shirin Bruderer; Noémie Hurst; Ruben de Kanter; Tommaso Miraval; Thomas Pfeifer; Yves Donazzolo; Jasper Dingemanse
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

9.  Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine.

Authors:  J Karbwang; S Looareesuwan; R E Phillips; Y Wattanagoon; M E Molyneux; B Nagachinta; D J Back; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

10.  The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.

Authors:  J H Rivière; D J Back; A M Breckenridge; R E Howells
Journal:  Br J Clin Pharmacol       Date:  1985-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.